Description
Dapagliflozin and Metformin Extended Release Tablets are a fixed-dose combination of two oral antidiabetic agents used for the management of type 2 diabetes mellitus (T2DM). This combination offers complementary mechanisms of action to improve glycemic control in adults, especially when lifestyle modifications and monotherapy are insufficient.
- Dapagliflozin is a SGLT2 inhibitor that reduces blood glucose levels by promoting urinary glucose excretion and also contributes to modest weight loss and blood pressure reduction.
- Metformin is a biguanide that lowers hepatic glucose production, enhances insulin sensitivity, and improves peripheral glucose uptake.
This extended-release formulation helps maintain steady blood glucose control while minimizing gastrointestinal side effects associated with immediate-release metformin.
Mechanism of Action:
- Dapagliflozin inhibits sodium-glucose co-transporter 2 (SGLT2) in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion.
- Metformin works by suppressing hepatic gluconeogenesis and improving insulin sensitivity in muscle and fat tissues.
Together, they provide additive glycemic control, improve HbA1c levels, and offer cardiometabolic benefits.
Indications:
- Type 2 diabetes mellitus in adults as an adjunct to diet and exercise
- When monotherapy with either agent does not provide adequate glycemic control
- May be used in combination with other antidiabetic agents, including insulin
